AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02033460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy and Education
Description: Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
Study NCT02033460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Education
Description: Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
Study NCT03285529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STRATIFIX
Description: STRATIFIX symmetric PDS Plus; Stratifix knotless suture
Study NCT03285529 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VICRYL
Description: Vicryl #1
Study NCT01416181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm
Study NCT01416181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo in part 1
Study NCT01332032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Reminder Letter
Description: A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
Study NCT01332032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Reminder Call
Description: A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
Study NCT01332032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Counselor Call
Description: Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
Study NCT04286308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological data collection
Description: Electrophysiological data collection at the time of DBS surgery.
Study NCT01399346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Application of 18 IU insulin aspart as one bolus at one injection site
Study NCT01399346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
Study NCT02812680 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
Study NCT04556604 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational meetings and visual prompts
Description: Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
Study NCT01821963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Starting dose: 180 mcg subcutaneously once weekly.
Study NCT01821963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Starting dose: 1,000 mg by mouth daily.
Study NCT01821963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Starting dose: 750 mg by mouth 3 times a day.
Study NCT02428140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Reveal LINQ
Study NCT02428140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorin Spiderflash-t
Study NCT03604614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
Study NCT03604614 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Without Hyperthermic Intraperitoneal Chemotherapy
Description: The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
Study NCT02351037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
Study NCT02351037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib + LD-AraC
Description: Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
Study NCT03520972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 75ug
Description: 60 eligible patients will be included in this group
Study NCT03520972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 150ug
Description: 60 eligible patients will be included in this group
Study NCT03520972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 200ug
Description: 60 eligible patients will be included in this group
Study NCT03520972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 60 eligible patients will be included in this group
Study NCT00106223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
Study NCT00106223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
Study NCT01229800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
Study NCT01229800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate(NaP) solution
Description: Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
Study NCT04206267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceledent
Description: Device for accelerating tooth movement
Study NCT03705117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V565
Description: Capsules for oral administration
Study NCT01571024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 40 mg, orally, once daily.
Study NCT01571024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
Study NCT01860573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino acids
Study NCT01860573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Study NCT02978131 — intervention group
Intervention type: OTHER
Intervention: Histopathological study
Study NCT02978131 — intervention group
Intervention type: OTHER
Intervention: Molecular study (Polymerase chain reaction)
Study NCT04426903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: webFitForAll
Description: PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
Study NCT02351037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib+Azacitidine
Description: Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
Study NCT04426903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
Study NCT02314390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Mindfulness-Based Cognitive Therapy
Description: The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
Study NCT02314390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual-Mindfulness-Based Cognitive Therapy
Description: The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
Study NCT02477137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone or tablet
Description: Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
Study NCT00392821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib
Study NCT00392821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001
Study NCT02033460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
Study NCT02033460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
Study NCT02033460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy, Education and Exercise
Description: Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
Study NCT03184714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: BiPAP treatment for 3 years
Study NCT01608854 — intervention group
Intervention type: OTHER
Intervention: Antibiotic Protocol
Description: Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
Study NCT02306499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI
Description: Intracytoplasmic Sperm Injection
Study NCT04641624 — intervention group
Intervention type: OTHER
Intervention: ultrasound assessment
Description: soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
Study NCT01984710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa PC+S System
Study NCT03013699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cruciferous and Dark Leafy Green Intervention
Description: Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
Study NCT03962049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linzagolix
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
Study NCT02653404 — intervention group
Intervention type: OTHER
Intervention: IGRA test (QTF-GIT)
Description: blood sample for QFT-GIT will be taken together with other routine blood samples
Study NCT01042782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 and MitomycinC
Description: RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks
Study NCT03882931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second
Study NCT03882931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
Study NCT03882931 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The investigators will simulate theta bursts pulses similar to the Theta Burst Transcranial Magnetic Stimulation groups but without stimulation.
Study NCT04325555 — intervention group
Intervention type: DRUG
Intervention: PrEP
Description: The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
Study NCT01687374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-84 parathyroid hormone
Description: 100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
Study NCT01687374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection daily for 8 weeks.
Study NCT03990844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Okra seed
Description: Noodle enriched with 10% and 20% Okra seed flour.
Study NCT03013699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Dietary Care
Description: Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
Study NCT03990844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Okra seed
Description: Noodle enriched with 10% and 20% Okra seed flour.
Study NCT00542815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: 3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
Study NCT00542815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Another Phosphate binder (Sevelamer)
Description: Current approved dosing recommendations for 12 weeks
Study NCT04634669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05 (dextromethorphan-bupropion)
Description: - AXS-05 tablet, taken daily (up to 15 months)
Study NCT04160221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 hours interval
Description: Time interval between treatments
Study NCT04160221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24 hours interval
Description: Time interval between treatments
Study NCT05402085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: Subjects will be provided with high protein diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
Study NCT05402085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: Subjects will be provided with high fat diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
Study NCT05402085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Carbohydrate-Low Glycemic Index Diet
Description: Subjects will be provided with high carbohydrate-low glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
Study NCT05402085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Carbohydrate-High Glycemic Index Diet
Description: Subjects will be provided with high carbohydrate-high glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
Study NCT03697408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: A JAK 1 selective small molecule inhibitor
Study NCT03697408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: A mammalian target of rapamycin (mTOR) inhibitor
Study NCT03128086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Description: A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
Study NCT01484912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-2
Description: After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.
Study NCT01484912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.
Study NCT00443560 — intervention group
Intervention type: OTHER
Intervention: Case controlled analysis of epidural labor analgesia patterns
Description: A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses